Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,380 result(s) found. Displaying page 267 of 2,219.
    «« First « Previous 263  264  265  266  267  268  269  270  271  Next» Last»»
    EudraCT Number: 2015-003562-90 Sponsor Protocol Number: VHCRP1405 Start Date*: 2016-06-17
    Sponsor Name:The Kirby Institute - UNSW Australia
    Full Title: A phase IV open-label, multicentre, international trial of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for people with chronic hepatitis C virus genotype 1 infection and...
    Medical condition: Chronic hepatitis C virus genotype 1 infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004848 10072844 Hepatitis C virus genotype 1a positive LLT
    19.0 100000004848 10072845 Hepatitis C virus genotype 1b positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-005165-31 Sponsor Protocol Number: LPS14914 Start Date*: 2020-05-14
    Sponsor Name:Sanofi Aventis Groupe
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Comparative Study to Assess the Efficacy and Safety of Spores of Enterogermina in Combination with Oral Rehydration Ther...
    Medical condition: Acute diarrhea
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10012735 Diarrhoea PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000165-23 Sponsor Protocol Number: INFORM Start Date*: 2016-10-19
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: ComparIsoN oF Optimal Hypertension RegiMens (Part of the Ancestry Informative Markers in Hypertension (AIM HY) Programme – AIM HY-INFORM)
    Medical condition: Cardiovascular Hemodynamics
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004848 10005727 Blood pressure LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-000342-22 Sponsor Protocol Number: VALACT-2017-01 Start Date*: 2017-04-04
    Sponsor Name:Dr. Luis Fernández-Dr. Jesus Barrio
    Full Title: A randomized, double-blind, placebo-controlled study of the usefulness of the probiotic 'Lactobacillus reuteri' in the therapy of quadruple eradication of Helicobacter pylori infection in usual cli...
    Medical condition: Helicobacter Pylori infection
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10019377 Helicobacter pylori infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-004532-30 Sponsor Protocol Number: MRZ60201_3091_1 Start Date*: 2014-12-09
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of...
    Medical condition: Chronic troublesome sialorrhea associated with neurological disorders (e.g. cerebral palsy, traumatic brain injury) and/or intellectual disability in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    19.0 10017947 - Gastrointestinal disorders 10039424 Salivary hypersecretion PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001972-70 Sponsor Protocol Number: PII116678 Start Date*: 2015-05-04
    Sponsor Name:GlaxoSmithKline Reasearch & Development
    Full Title: A randomised, double-blind (sponsor unblinded), placebocontrolled, parallel-group, multicentre study to evaluate the efficacy and safety of GSK2269557 administered in addition to standard of care i...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) DK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-005721-39 Sponsor Protocol Number: I5B-MC-JGDN Start Date*: 2016-06-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-dose Ifosfamide in Pediatric Patients with Relapsed...
    Medical condition: Neoplasm Metastasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10049280 Solid tumour LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000188-15 Sponsor Protocol Number: AL1402ac Start Date*: 2017-01-09
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicenter randomized double-blind placebo-controlled clinical trial for evaluation of efficacy and safety of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation o...
    Medical condition: allergic bronchial asthma and allergic rhinitis or rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10039097 Rhinoconjunctivitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed) LT (Completed) DE (Completed) ES (Completed) LV (Completed) AT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001660-29 Sponsor Protocol Number: FAB18 Start Date*: 2019-01-16
    Sponsor Name:Leiden University Medical Center
    Full Title: FAB: Functional Analysis of BRCAness
    Medical condition: Recurrent epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000691-94 Sponsor Protocol Number: CHUBX2014/35 Start Date*: 2016-01-29
    Sponsor Name:CHU de Bordeaux
    Full Title: Self-help program for hypnotics withdrawal in insomniac patients: A randomized controlled clinical trial.
    Medical condition: Insomnia Chronic hypnotic users
    Disease: Version SOC Term Classification Code Term Level
    18.0 10037175 - Psychiatric disorders 10022437 Insomnia PT
    18.0 100000004869 10013662 Drug and chemical abuse HLT
    18.0 10037175 - Psychiatric disorders 10053851 Chronic insomnia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003156-49 Sponsor Protocol Number: RMTX-CL001 Start Date*: 2015-11-05
    Sponsor Name:RegenMedTX, LLC
    Full Title: A Phase II, Open-Label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease
    Medical condition: Chronic Kidney Disease (CKD) in patient with type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    18.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002301-29 Sponsor Protocol Number: SL-51A Start Date*: Information not available in EudraCT
    Sponsor Name:ROXALL Medicina España S.A.
    Full Title: PHASE II STUDY TO ASSESS THE TOLERABILITY, SAFETY AND EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PATIENTS SUFFERING FROM GRASS POLLEN ALLERGY
    Medical condition: Patients with grass pollen related allergic rhinitis/rhino-conjunctivitis (with or without well controlled asthma).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005639-10 Sponsor Protocol Number: 116725 Start Date*: 2015-07-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open, multi-center study to evaluate the long-term anti-body persistence at 6, 7, 8, 9 and 10 years after the administration of one dose of GlaxoSmithKline (GSK) Biologicals’ meningoc...
    Medical condition: prevention of invasive disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y in healthy subjects aged 11 to 55 years of age)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002381-31 Sponsor Protocol Number: Quadrimeningofollowu Start Date*: 2016-07-22
    Sponsor Name:Public Health England
    Full Title: An observational follow up study of a phase II/III, open label, randomised study of the safety, reactogenicity and immunogenicity of a single dose of meningococcal ACWY conjugate vaccine (Menveo, G...
    Medical condition: No specific medical condition(s) - responses to vaccination against meningococcal disease.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10027199 Meningitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004060-35 Sponsor Protocol Number: IPP-201101/006 Start Date*: 2018-03-12
    Sponsor Name:ImmuPharma
    Full Title: An open-label study of the safety and tolerability of repeated administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-002531-18 Sponsor Protocol Number: 69HCL16_0062 Start Date*: 2018-10-31
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Topical Everolimus versus placebo for the treatment of facial angiofibromas in patients with tuberous sclerosis complex. A phase II/III, multicentre, randomized, double-blind, placebo-controlled st...
    Medical condition: angiofibromas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002429 Angiofibroma PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001448-24 Sponsor Protocol Number: RG_20-029COVID-19 Start Date*: 2020-04-15
    Sponsor Name:University of Birmingham
    Full Title: Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
    Medical condition: Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10035664 Pneumonia PT
    21.1 100000004855 10003083 ARDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-000052-29 Sponsor Protocol Number: VIPV-04 Start Date*: 2014-09-17
    Sponsor Name:Statens Serum Institut
    Full Title: Safety and immunogenicity of 3 adjuvated reduced dose inactivated poliovirus vaccines (IPV-Al SSI) and non-adjuvated full dose IPV SSI, given as a booster vaccination to adolescents with a hi...
    Medical condition: Profylactic immunisation against poliomyelitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10054187 Polio immunization LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004734-25 Sponsor Protocol Number: V72P3 Start Date*: 2014-11-11
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine OMV When Administered at an 0-2-6-Month Schedul...
    Medical condition: Prophylaxis Aganist Invasive Meningococcal Disease
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000133-70 Sponsor Protocol Number: V130_03 Start Date*: 2015-01-09
    Sponsor Name:Novartis Vaccines and Diagnostics, Inc
    Full Title: A Phase III, Stratified, Randomized, Double-Blind, Multicenter, Non-Inferiority Study to Evaluate Safety and Immunogenicity of Cell-Based Quadrivalent Subunit Influenza Virus Vaccine and Cell-Based...
    Medical condition: Prophylaxis of A Three Influenza Vaccines in Children Ages 4 Years Old to Less Than 18 Years Old
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 263  264  265  266  267  268  269  270  271  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Feb 10 15:57:12 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA